Study was terminated as per BARDA decision to terminate contract.

This Phase 1/2 protocol is designed to collect safety, tolerability and pharmacokinetic data of two doses of Laninamivir Octanoate in children and adolescents. The protocol will also explore virology and efficacy endpoints.

Approximately 48 subjects aged 5-17 years inclusive will be randomised into the study.

Subjects with recent onset of presumptive influenza will have influenza A or B infection confirm by Rapid Antigen Test.

The study will be conducted on an outpatient basis. The dose is administered in a single session in the clinic on Day 1. The subject will return to the clinic for assessments and follow up.

Inclusion Criteria:

• Subjects' parent/legally acceptable representative/guardian must give written informed consent to participate in the study and must understand the nature of the study and must be willing to comply with all protocol requirements. Subjects over 12 must provide assent to participate in the study and potential subjects below this age should provide assent if deemed appropriate to the maturity level of the subject or if required according to local guidance/regulations.

• Males or females aged between 5 and 17 years inclusive, who weigh at least 15 kg at screening.

• Confirmed influenza infection based on positive rapid antigen test (RAT) for Influenza A or B.

• Fever, defined as either:

  1. Otic temperature ≥38.0° C (100.4°F) at the screening visit, OR,
  2. A history of fever within the 24 hours prior to the screening visit and has administered antipyretic(s) in the 6 hours prior to the screening visit.

• Presence on the Screening questionnaire of, at least two, of the following influenza symptoms:

  1. Non-productive Cough, of at least moderate severity,
  2. Sore throat, of at least moderate severity,
  3. Nasal congestion/runny nose, of at least moderate severity,
  4. Headache, of at least moderate severity,
  5. Muscle aches and pain, of at least moderate severity,
  6. Feeling feverish, of at least moderate severity,
  7. Low energy, tired, fatigue, of at least moderate severity;

• Onset of illness no more than 40 hours before randomization, defined as:

  1. time when the temperature was first measured as elevated ≥38.0°C (oral or otic) OR
  2. time when the subject first experienced at least one influenza symptom (non-productive cough, sore throat or nasal congestion/runny nose, headache, muscle aches and pain, feeling feverish, or low energy/tired/fatigue)

• In the Investigator's opinion able to complete the required inhalations of the investigational medicinal product.

Exclusion Criteria:

• Use of antiviral treatment for influenza (e.g., zanamivir, oseltamivir, peramivir, rimantadine, or amantadine) within 14 days prior to screening
• Received influenza virus vaccine in the previous 3 weeks.
• History or presence of clinically significant pulmonary disease (e.g., chronic obstructive pulmonary disease, cystic fibrosis, or bronchiectasis)
• Current asthma requiring treatment, or history of asthma requiring treatment in the last 5 years, or episode of wheezing in the 12 months prior to randomization.
• History of congestive heart failure with symptoms consistent with New York Heart Association Class III or IV functional status.
• Presence of an immune compromised status due to chronic illness, organ transplantation or use of daily systemic immunosuppressants
• Presence of clinically significant signs of acute respiratory distress during screening.
• Current use of inhaled medications (nasal or oral) or anticipated use of inhaled medications (nasal or oral) at any time during the study.
• Current or a history of acute or chronic renal impairment/disease
• Currently hospitalized or any planned hospitalizations within 1 month following the last dose of IMP.
• Current clinical evidence of otitis, bronchitis, sinusitis, or pneumonia or active bacterial infection at any body site
• Severe infection within 30 days prior to screening which required parenteral antibiotic use or hospitalization.